Trichloroethylene (TCE) induces liver cancer in mice but not in rats. Three metabolites of TCE may contribute-chloral hydrate (CH), dichloroacetate (DCA), and trichloroacetate (TCA). CH and TCA appear capable of only inducing liver tumors in mice, but DCA is active in rats as well. The concentrations of TCA in blood required to induce liver cancer approach the mM range. Concentrations of DCA in blood associated with carcinogenesis are in the sub-pM range. The carcinogenic activity of CH is largely dependent on its conversion to TCA and/or DCA. TCA is a peroxisome proliferator in the same dose range that induces liver cancer. Mice with targeted disruptions of the peroxisome proliferator-activated receptor alpha (PPARa) are insensitive to the liver cancer-inducing properties of other peroxisome proliferators. Human cells do not display the responses associated with PPARa that are observed in rodents. This may be attributed to lower levels of expressed PPARax in human liver. DCA treatment produces liver tumors with a different phenotype than TCA. Its tumorigenic effects are closely associated with differential effects on cell replication rates in tumors, normal hepatocytes, and suppression of apoptosis. Growth of DCA-induced tumors has been shown to arrest after cessation of treatment. The DCA and TCA adequately account for the hepatocarcinogenic responses to TCE. Low-level exposure to TCE is not likely to induce liver cancer in humans. Higher exposures to TCE could affect sensitive populations. Sensitivity could be based on different metabolic capacities for TCE or its metabolites or result from certain chronic diseases that have a genetic basis. Key words: chloral hydrate, dichloroacetate, liver tumors, mode of action, trichloroacetate, trichloroethylene. -Environ Health Perspect 108(suppl 2):241-259 (2000). http.//ehpnetl.niehs.nih.gov/docs/2000/suppl-2/24 1-259bull/abstract. html
Trichloroethene (TCE) presents an interesting problem in environmental risk assessment. Acutely, it is much less toxic than chlorinated hydrocarbon solvents that were developed early (e.g., carbon tetrachloride, chloroform) (1) . The chlorinated hydrocarbons had replaced the extremely flammable petroleum distillates used previously for many industrial applications. Because of the combination of low acute toxicity and flammability, TCE came into broad use as a solvent and degreasing agent. This broad usage led to inappropriate disposal. The high mobility of TCE in the subsurface and the relative ease by which it can be measured at very low concentrations virtually guaranteed that it would become a pivotal chemical in the development and application of rules and regulations where intent has been to protect the public health (2) .
The major economic reason for reexamining the risk assessment for TCE is that it is frequently a difficult problem for compliance with certain environmental laws, particularly the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA). Compliance with these laws has been responsible for much of the costs associated with cleanup of uncontrolled hazardous waste sites. The national costs for cleanup are huge, running into the billions of dollars (3) . Therefore, relaxation of cleanup standards could save considerable public and private resources. However, reevaluation of this potential carcinogenic risk against proposed cancer risk assessment guidelines of the U.S. Environmental Protection Agency (U.S. EPA) (4) has broader implications. The metabolites of TCE thought responsible for its induction of liver tumors are also produced in the chlorination of drinking water (5) . In the case of drinking water disinfection, the putative cancer risks from the formation of these compounds need to be balanced with the clearly established benefits of chlorination in the protection of public health from waterborne infectious disease (5, 6) .
Aside from its importance in the public policy arena, TCE is a classic example of a chemical that affects different target organs in different species and strains of experimental animals. This presents a challenge to risk assessment because the risk to humans can only be established by careful consideration of the mechanisms by which each cancer is produced. In some species, differing target organs may be attributed to quantitative differences in predominant pathways of metabolism (7) (8) (9) . Clearly, different metabolites of TCE target different organ systems. However, there also appear to be some intrinsic species differences in susceptibility to the effects of these metabolites.
In general, the tumor site in each species or strain in which TCE induces cancer corresponds to those sites in which the spontaneous frequency is greater for that strain or species. It may be reasonably assumed that sufficient numbers of initiated cells are present in such organs and a variety of mechanisms could accelerate the development of these spontaneous tumors. The contribution of some of these mechanisms or modes of action to carcinogenesis may not be linear at low doses.
The focus of this review is the induction of hepatic tumors by TCE. The probability (possibility) that this response is strain specific will be considered in the context of which metabolites are most likely to be responsible. Second, the possibility must be considered that the same mechanisms that have been identified in the sensitive strain (B6C3F, mice) provide a more general warning or alert that TCE could present a hazard in humans for cancer. The effects of TCE on other target organs are considered by other authors (8, 9) .
In the course of this review, four modes of action are considered as they relate to the induction of liver tumors: somatic mutation, modification of cell signal pathways (peroxisome proliferation; other mechanisms that modify cell replication and death rates), cell death and reparative hyperplasia, and hepatomegaly/cytomegaly.
Ability of TCE to Induce Hepatic Cancer TCE and several of its metabolites have been shown to produce hepatic cancer in experimental animals. Table 1 lists carcinogenesis bioassays in which TCE induces hepatic cancer, followed by a listing of studies in which liver tumor induction was evaluated but not found. Essentially, these data show that TCE only produces liver tumors in selected strains of mice (B6C3F, and Swiss) (10) (11) (12) despite adequate studies in several strains of rats (13) and in hamsters (14) . A number of studies in other strains of mice have also been negative for liver tumor induction even though the dosing schedule and duration of the studies should have been R.J. BULL 
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F: 0, 0%; 100, 0%; 300, 0%; 600, 1.1% Abbreviations: B, both sexes; COG, corn oil gavage; F, female; H, high; L, low; M, male. &Early mortality resulted in second experiment in male B6C3F, mice. adequate; e.g., ICR mice (15) and male and female ICR-HA mice (14) . While TCE induced liver tumors only in mice administered by corn oil gavage, it produced tumors at other sites in mice via inhalation and rats via inhalation or gavage (12, 16) . It has also been associated with small excess risks for liver cancer and other tumor sites in epidemiologic studies (17) .
The epidemiologic evidence provides some support for the hypothesis that TCE poses a liver cancer risk in humans; however, this evidence is not strong. The International Agency for Research on Cancer (IARC) (1) recently concluded that limited evidence existed for liver cancer but that risk was not consistent across all studies. IARC placed greatest weight on three studies of occupational exposure: the Spirtas et al. (18) study of aircraft workers and two studies of solventexposed workers, Axelson et al. (19) and Anttila et al. (20) . When (20) , and one other study of the Hughes Aircraft employees (21) .
These studies indicated a total of 16 cases of primary liver cancer (a category that excludes cancer of the biliary tract) in which 9.5 were expected. Weiss (17) cautioned that the modest size of the increased risk and the lack of an exposure trend in the Spirtas et al. (18) study provide limited support for a causal hypothesis.
Evidence ofSomatic Mutation
Produced by TCE There have been several reviews published on the mutagenic effects of TCE and its metabolites (22, 23) . An (23) . Therefore, data on the mutagenic effects will be confined to considerations of evidence that a chemically induced somatic mutation plays a role in the development ofliver tumors.
The only evaluations of genotoxicity data of TCE that are directly relevant to liver tumor induction were studies of in vivo unscheduled DNA synthesis in rats and mice (25) (26) (27) (30, 31) . No specific adducts could be isolated (31, 32) . Bergman (32) (33, 34) . Once in this pool, the label can be incorporated into other amino acids, such as alanine, that were not measured. Therefore, simple association of label cannot be accepted as evidence of covalent interaction with TCE and any metabolites of its oxidative pathway (34) . Glycine is also a precursor for DNA synthesis. Caution must still be exercised, as new studies that focus on incorporation of label using more sensitive techniques have been performed without apparent appreciation of this problem (35) . While these studies certainly overestimated the amount of covalent binding of TCE to protein, additional work has provided evidence of covalent binding to protein by correction for metabolic incorporation (34) or through the use of immunochemical techniques (36) . These data suggest that the ability of TCE or its oxidative metabolites to interact with hepatic DNA directly is very limited.
Elevated levels of products of lipid peroxidation and 8-hydroxy-2-deoxyguanosine/ 2-deoxyguanosine ratios have been observed in the liver of rats treated with TCE at a dose of 1,000 mg/kg but not at 500 mg/kg (37) . Free radicals have also been trapped when TCE is incubated with liver slices in vitro (38) . Consequently, there is the possibility that radicals may contribute to the carcinogenic response. In part, these effects could contribute to the tumor response by increasing mutation rates in the target tissues. However, these effects become less of a concern at lower doses because of the much higher levels of similar damage produced by the normal energy metabolism of the body. Oxidative stress is also closely associated with tumor promotion mechanisms (39 Anna et al. (40) and Ferreira-Gonzalez et al. (43) independently assessed the frequency of H-ras mutations and spectra in dichloroacetate (DCA)-induced tumors. These published data and those of historical controls for male B6C3F1 mice (40) specifically at codon-61 of H-ras are displayed in Table 2 . The mutation frequency in DCAinduced tumors does not differ significantly from that observed in spontaneous tumors. However, there is an obvious change in the mutation spectra in codon 61, involving a significant increase in the H~ras-61CA mutation at the expense of the H-ras-61AAA mutation. The mutation spectra found in DCA-induced tumors has a striking similarity to those observed in TCE-induced tumors and is different than those of TCAinduced liver tumors.
New data are becoming available that have only been reported in abstract form (44) . As noted in Table 2 , the mutation spectra of mouse liver tumors obtained from mice treated with TCA appear to be different than those induced with DCA (43). Only 11 TCAinduced tumors, of which 5 had detectable mutations in codon 61 of H-ras, were utilized in this analysis. The new data (44) indicate a mutation frequency in a larger number of TCA-induced tumors (n = 30) of 0.53. The ratio of AAA:CGA:CTA in codon 61 was found to be 3:2:1 (44). DCA-induced tumors were found to have a low mutation frequency (0.33) and to have an excess of the CTA mutation (ratio = 6:7:7), showing the same shift from the AAA to the CTA mutation reported previously (42) . In contrast with previous data, tumors were examined in animals that had been treated with TCE in an aqueous vehide. These tumors had a lower mutation frequency than the previous data from tumors induced by TCE in a corn oil vehicle (0.24 vs 0.51). However, the mutations spectra were 3:2:5, similar to those reported previously (42) for TCE-induced tumors (ratio = 6:5:9). The lower mutation frequency and the relative enrichment of the CTA mutation with TCE and DCA suggest a common mechanism. Thus, DCA may play a role in the hepatocarcinogenicity of TCE in mice despite its low level of formation (discussed later). It is notable that a mutation frequency lower than historical controls, as seen with TCE when administered in water rather than corn oil and with DCA, are more consistent with the activity of other chemicals that act as tumor promoters (42) . The relatively high mutation frequency found with TCA is atypical of other peroxisome proliferators (42) .
Difficulties in interpreting mutation spectra are just coming to light. The presence or absence of ras mutations cannot be correlated with the extent to which ras-dependent pathways are expressed in the liver (45) . Recently, it was found that tumors induced by DCA in female B6C3Fi mice had a very low frequency of H-ras mutations (46) . Consequently, it is difficult to conclude that the induction of H-ras mutations plays an initiating role for liver cancer in mice.
It is important to consider the large differences in blood levels of DCA that are achieved by minimally carcinogenic doses and those used in the experiments in which mutation spectra were measured. As indicated above, the concentrations of DCA measured in the blood of male B6C3F, mice drinking 0.5 g/L were found to be 2-3 pM, whereas in mice consuming 2 g/L of DCA concentrations were found to be 300 pM during the period of active water consumption (47) . Blood concentrations of DCA in mice gavaged with 1,000 mg/kg TCE are less than 2 pM, the limit of quantitation in the early studies (50, (67) (68) (69) 
Metabolism of TCE
The metabolism of TCE is schematically depicted in Figure 1 . This is simply to identify where those metabolites considered most likely to produce hepatic tumors fit into the metabolic scheme. Other reviews will more thoroughly address the characteristics of the individual metabolic steps and their variation between species (11) and the pharmacokinetics ofTCE and critical metabolites (70) . From (77, 78) , as it is produced by rearrangement of a trichloroethyleneoxygen-cytochrome P450 complex (79) . CH is either rapidly reduced to trichloroethanol (TCOH) or oxidized to TCA. In most species, TCOH is rapidly glucuronidated and the glucuronide is secreted into the bile. It is then secreted into the small intestine, hydrolyzed back to TCOH in the gut, reabsorbed and available to either be oxidized to TCA through CH as an intermediate, or reconjugated with glucuronic acid (80) (81) (82) (83) . Normal humans are proficient at glucuronidating TCOH relative to rodents, particularly mice (9, 82) . Deficiencies in the ability to glucuronidate chemicals are, however, relatively frequent in the human population.
The glutathione pathway of TCE does lead to the formation of a clearly mutagenic metabolite, dichlorovinylcysteine (84) . The N-acetyl derivative of this metabolite has also been identified in both rat (85) and human urine (86) , and it has been postulated responsible for renal tumor induction in the rat (85) and possibly in humans (87) (88) (89) (71) . Parallel data on pathology and serum enzyme levels indicate that CH was minimally cytotoxic at these doses in mice. Therefore, the apparent greater sensitivity of mice (albeit of another strain) to the hepatocarcinogenic effects of CH than rats appears to parallel the sensitivity for cytomegaly. Clearly, the liver-enlarging effects of CH are observed in the same dose range (166 mg/kg) at which tumors were induced (71) . Neither the effects nor the dose required to produce these effects appears consistent with a contribution of CH to liver tumor induction by TCE that is independent of the contributions of subsequent metabolites (DCA and TCA).
Hepatocarcinogenicity of Tnichloroacetate
Trichloroacetate induces hepatocellular carcinomas when administered in drinking water to male and female B6C3F1 mice (72) (73) (74) . In these studies, dose-related increases in the incidence of malignant tumors and precancerous lesions have been obtained at concentrations in water of between 1 and 5 g/L with as little as 12 months of treatment (73, 74, 92 (93) .
Effects on the liver that could contribute to tumorigenesis. Genotoxic effects. Early reports indicated that TCA induced SSBs in the hepatic DNA of mice and rats (28, 107) . Subsequent experiments using the same methodology (108) failed to replicate the increase in SSBs observed in mice, using a single, high 500 mg/kg dose. Using slightly different methodology, Chang et al. (109) found a very small but statistically significant increase in SSBs with a dose of 1,600 mg/kg TCA to mice but no effect at 800 mg/kg. More recent data indicate that an oral dose of 300 mg/kg TCA has been shown to increase oxidative damage to DNA, as measured by increased content of 8-hydroxy-2-deoxyguanosine (8-OH-dG) content of nuclear DNA of the liver when administered in acute doses (110) . However, this response was small and not observed when male B6C3F1 mice were treated with 2 g TCA/L in drinking water for 3 or 10 weeks (111). Nevertheless, lipofuscin deposits are prominent in the liver of chronically treated mice, demonstrating some ongoing oxidative stress in response to TCA (73) . Lipofuscin is, however, absent from TCA-induced tumors.
The totality of the data that are available suggests that TCA is unlikely to damage DNA directly, although there may be some damage that is induced by indirect mechanisms at very high doses. It is important to recognize that oxidative damage to DNA is rapidly repaired (112) . Therefore, the small changes in the background levels of 8-OH-dG in DNA produced at very high doses may play little, if any, role in TCA's contribution to the hepatocarcinogenic responses to TCE.
Bull et al. (73) found that suspension of treatment at 37 weeks resulted in a smaller number of total tumors in mice at 52 weeks than in mice that had been treated continuously for the entire 52 weeks based upon total dose administered. These data suggest that benign lesions induced by TCA regressed when treatment was suspended at 37 weeks and support the hypothesis that TCA is not genotoxic. However, most of the tumors that remained in the group in which treatment was suspended were hepatocellular carcinomas (3 of 5). This was in contrast to the fact that only 4 of 16 tumors were found to be hepatocellular carcinomas in mice kept on continuous treatment.
The initiation-promotion study of Pereira and Phelps (113) also included a suspended treatment segment. These experiments were conducted in female rather than in male B6C3F1 mice. TCA increased the yield of both hepatocellular adenomas and carcinomas in methylnitrosourea (MNU)-initiated mice (Figure 2 ). TCA significantly increased the yield of hepatocellular carcinoma as well as hepatocellular adenomas after 362 days of treatment. The mice whose treatments were suspended at 37 weeks had significantly reduced numbers and incidences of hepatocellular carcinomas at 52 weeks relative to initiated mice treated for the full 52 weeks with TCA. The hepatocellular carcinoma yield within the group that had its treatment suspended was very close to what would have been expected from adding the incidence of the MNU-only and TCA-only treatment groups. In the initiated mice, the incidence of hepatocellular adenomas was increased to essentially the same multiplicity whether at 31 weeks, 52 weeks, or in animals whose treatments were suspended at 31 weeks and who were sacrificed at 52 weeks. Hepatocellular adenomas were very few in mice treated with TCA alone. While hepatocellular adenomas were at a higher incidence and multiplicity with TCA than with MNU alone, they appeared remarkably insensitive to any change in the treatment period for TCA.
There is a consistency with the observations of Bull et al. (73) that suggests that the hepatocellular carcinomas arise from the similar cell populations with TCA treatment in both the whole carcinogenesis and the initiationpromotion study. Another publication (114) reports that 27% of TCA-promoted tumors derived from the B6C3F1 hybrid mice from the Pereira and Phelps (113) study lost heterozygosity on chromosome 6 . There was no loss of heterozygosity in this chromosome in DCA-promoted tumors, indicating that the effect was not attributable to the initiator. As a consequence, these data imply that either the initiated cells promoted by TCA to hepatocellular carcinomas are susceptible to this clastogenic result spontaneously (something that is known to happen both clinically and experimentally) or that TCA could be acting as a tumor progressor. The very weak activity of TCA to act as a clastogen provides some basis for the former hypothesis (115) .
Modification of cell-signaling pathways. TCA induces peroxisome proliferation in male B6C3F1 mice over the same dose range that it induces hepatic tumors (76) . Unlike the situation with DCA, discussed in the next section, increased expression of peroxisomes by TCA appears to be sustained over time. TCA also induces peroxisome synthesis in F344/N rats, but the increases in acyl-CoA oxidase activity were only 2-3 times the control levels at the concentrations administered in the drinking water (93, 116) . This compares to a 10-fold increase in this peroxisome marker with similar dosing schedule in mice. It is rare that such a small effect on peroxisome proliferation would be tied to carcinogenesis.
It is notable that Elcombe (50) found that the Wistar rat was actually more sensitive than mice to increases in cyanide-insensitive acyl-CoA oxidase activity induced by TCA. Obviously, this is inconsistent with the relative sensitivity of these two species to the tumorigenic effects of TCA in that rats (in this case F344) appear to be less sensitive than mice (B6C3F1) (116) . These results may reflect a strain difference or they may be attributed in part to the weak peroxisome proliferative activity of corn oil, which was the vehicle used by Elcombe (50) .
Modifications in rates of hepatocyte replication and death. The available data suggest that TCA has tumor-promoting activity. Stauber and Bull (117) induced tumors with TCA at 2 g/L for 50 weeks. In Figure 3 , the replication rates of TCA-induced tumors are shown. The rates within tumors from mice in which TCA administration had been suspended for 2 However, concentrations as low as 0.5 g/L will result in a hepatic tumor incidence of approximately 80% in a full 2-year study (76) . Hepatic tumors are also induced by DCA in male F344 rats (90, 91) . High doses of DCA given to rats produced a peripheral neuropathy (122, 123) that complicated the conduct of cancer bioassays. Nevertheless, increased incidence of hyperplastic nodules and hepatocellular adenomas and carcinomas was observed at 60 weeks of treatment at 2.4 g/L ( Table 3) . As in mice, if DCA treatment was extended to 104 weeks, the incidence of these lesions was 41% in a group of 29 rats at a treatment concentration of 0. ig/mL in the presence of S9. There was also a positive response with the SOS chromotest at 500 pg/mL. The newt micronucleus assay was negative. It appears that the free acid was also used in these studies, as there was no indication that the acids were neutralized. Therefore, the value of these data is limited because of the potential of pH artifacts (127) .
The mutagenic activity of sodium DCA was explored in a variety of test systems by Fox et The concentrations at which these genotoxic effects occur are important in determining whether they play a role in either DCA-or TCE-induced liver cancer. The lowest dose of DCA that has been shown to produce an increased incidence of cancer is 0. . Available data suggest that less DCA is formed in the metabolism of TCE by rats and humans (70) .
In vivo experiments. DCA was reported to induce SSBs in hepatic DNA when administered by gavage to both mice and rats (28, 107) . Subsequent investigators were unable to repeat these results (92, 109 (47) . Consequently, it is unlikely that these two effects are produced by the same mechanism.
DCA increases the deposition of glycogen in the liver. The dose response for glycogen deposition in the liver is in the same range that is required for inducing hepatocarcinogenesis (47) . The accumulation of glycogen with DCA treatment takes a pathological character, becoming resistant to mobilization by fasting after 8 weeks of treatment. Increased hepatic glycogen is capable of inhibiting glycogen synthase, an effect that is observed in the liver of DCA-treated mice (47) . However, DCA does not inhibit glycogen synthase when incubated with liver homogenates in vitro. The correlation of doses raises the possibility that the accumulation of glycogen and induction of tumors by DCA could be produced by modification of the same cell-signaling pathways.
Overexpression of the insulin receptor 1 substrate in human liver cells is known to be a suppressor of transforming growth factor PI (TGF-pl)-induced apoptosis (135) . Since Figure 4 . At a concentration of 2.6 g/L of drinking water, DCA induced a large increase in the number of hepatocellular adenomas but had no significant effect on the induction of hepatocellular carcinomas.
The data of Pereira and Phelps (113) appear to be at least partially consistent with the stop experiments of Bull et al. (73) . The latter authors found that suspending the treatment of male B6C3F, mice with DCA at 37 weeks appeared to arrest progression of liver tumors but resulted in a yield of hepatocellular adenomas and nodules that were proportional to the total dose of DCA administered. The initiation-promotion experiments of Pereira and Phelps (113) included a suspension of treatment with DCA at 31 weeks. This resulted in a substantial decrease in the numbers of MNUinitiated hepatocellular adenomas in female B6C3Fi mice at 52 weeks, with little effect on hepatocellular carcinoma yields. Nevertheless, there is an inconsistency with prior data. Bull et al. (73) found that the number of DCA-induced lesions were proportional to the total dose administered to the animal whether treatment was terminated at 37 or 52 weeks. The total number of lesions seen in the Pereira and Phelps (113) study was significantly less than would be predicted. It is probable that the differences between the two studies are related to the use of female rather than male mice and/or a tumor initiator in the latter study.
It is notable, however, that the total lesion numbers (foci + adenomas + carcinomas) observed by Pereira and Phelps (113) The question is whether this suppressive effect on cell turnover increases the probability of transformation of hepatocytes or clonal expansion of damaged hepatocytes that would normally be eliminated. Stauber et al. (119) determined the extent to which DCA could selectively stimulate the growth of clones of cells derived from the liver of naive B6C3F1 mice on soft agar. Figure 6 indicates the time-dose-response relationships that result when the only treatment of cells is the indicated concentrations within the Petri dish. DCA substantially increased the numbers of colonies over those that would grow out spontaneously. A most promising aspect of this result is that the colonies that grew out with DCA faithfully reproduced the phenotype (c-Jun+) of the tumors that were produced in vivo. The opposite phenotype was produced in TCAinduced tumors and in clones of cells derived from mouse liver that were grown in the presence of TCA on soft agar. A second experiment was conducted where male B6C3F1 mice were treated with a minimally carcinogenic concentration of DCA in drinking water for 14 days and the in vitro segment of the experiment repeated. This experiment was predicated on the notion that if the main effect of DCA is to produce clonal expansion, then the number of cells isolated should increase with in vivo treatment. This occurred as predicted. However, it was also noted that the sensitivity of the cells obtained from treated animals to DCA in the soft agar had substantially increased. animals that had been pretreated. Statistically significant increases in the numbers of colonies were observed at the lowest concentration studied, 20 1M. There was no statistically significant effect on the number of colonies produced from plating a standard number of hepatocytes from naive mice until the dose was increased above 200 1sM.
Miller and co-workers (138) directly examined the effect of DCA treatment on liver tumor growth rates in mice in vivo using magnetic resonance imaging. DCA was administered to mice until small tumors became apparent (-1 mm in diameter). The animals with tumors were randomly assigned to two groups, one in which treatment was maintained and the other in which treatment was suspended, and the tumors imaged over the next 2-3 weeks. The results of this study are shown in Figure  8 . Cessation of DCA treatment essentially abolished the growth of tumors. These data were modeled to determine if the small lesion size distribution found in previous studies (117) could be accounted for by the effects of DCA on tumor growth. The growth data and prior measurements of the effects of DCA on replication rates within tumors (117) , assuming a suppression of apoptosis in this cell population was of the same magnitude noted in normal hepatocytes of DCA-treated mice (137) , accounted for the lesion size distribution.
Cytotoxicity and reparative hyperplasia. Early reports (120) indicated that high doses of DCA produced localized lesions in the liver. These lesions led to localized increases in the labeling index. Subsequent pathological analysis of slides identified the lesions as acinar necrosis (139) . More recently, DeAngelo and co-workers (76) developed a dose-response characterization of the severity of these lesions. A curve derived from these data is provided in Figure 9 . Necrosis never involved large portions of the liver as indicated by the relatively low scores, and was confined to treatment levels > 1 g/L. No difference from control animals was observed at doses of 0.5 g/L. A liver tumor incidence of approximately 80% is observed at this treatment level (76, 117 Figure 9 . Severity of necrotic damage to the liver in male B6C3F1 mice treated with various doses of DCA for different periods of a lifetime experiment. Note that such damage varies significantly in time but is only observed at doses of 1 g DCA/L drinking water and above. The necrosis involves limited portions of the liver (acinar necrosis). Data are adapted from DeAngelo et al. (76) , but are typical of experiences in other laboratories (119, 120) . Each value represents the mean of scores in the livers of 10 mice ± SEM. F344 rats chronically administered DCA. This conclusion is inconsistent with reports in other strains of rat. However, the design of the study may have tended to mask the hepatomegaly. The high dose of DCA was adjusted downward (from 2.6 to 1 g/L) after 18 weeks of treatment to avoid signs of overt toxicity in the rat. The earlier treatment clearly resulted in substantial losses in body weight that were apparently not recovered over the 84 weeks of the study. There were significantly elevated liver-to-body weight ratios in this group and an increase in both absolute and relative liver weights at the next lowest dosing schedule (0.5 g/L), the level associated with induction of liver tumors in a 2-year bioassay (91) .
The dog appears to be very sensitive to the effects of DCA on the liver. Cicmanec et al. (141) examined the subchronic effects of DCA in dogs. Dogs were administered 12.5, 39.5, and 72 mglkg/day for 90 days to groups of five males and five females. Liver weights were significantly increased in a doserelated manner beginning with the lowest dose. By comparison, the lowest effect level noted in mice is at 0.5 g/L of drinking water, which approximates 70-100 mg/kg per day, while the lowest effect level appears to be 125 mg/kg in rats (122) . Thus, the hepatomegaly induced by DCA is consistently observed across species.
Comparing the Tumors Induced by DCA and TCA Hyperplastic nodules and tumors induced by DCA have some characteristics that distinguish them from nodules and tumors that are induced by TCA. Pereira (74) indicated that in female mice both hepatocellular adenomas and carcinomas induced by DCA tended to be eosinophilic, whereas those induced by TCA were basophilic. In male B6C3F1 mice treated with 2 g DCA/L, a substantial fraction (66%) of the AHF and nodules were reported to be eosinophilic (117) . However, the larger lesions tend to be basophilic. These larger lesions included hyperplastic nodules, adenomas, and carcinomas. These data suggest that there are some differences in tumor induction by DCA based on sex. However, this difference appears to be important primarily at high doses (2 2 g/L) where the rate of cell replication is enhanced in a set of basophilic lesions. The development of these lesions may account for the much shorter latencies observed in male vs female mice at high doses (73) .
As pointed out by previous investigators examining responses in male mice (73, 75) , Pereira et al. (74) found that the slope of the dose-response curves describing the induction of total lesions by DCA increases disproportionately with dose in female mice. A very similar nonlinear relationship was observed in the initiation-promotion study (113) . Conversely, the carcinogenic responses to TCA are essentially linear with dose in both types of studies. In part, the nonlinear character of the DCA dose-response area is a function of auto-inhibition of its metabolism as dose increases (47, 142) .
Stauber and Bull (117) found that DCAinduced liver tumors in male B6C3F, mice were immunoreactive to c-Jun and c-Fos antibodies, whereas TCA-induced liver tumors were not. It was found that this difference in phenotype could be duplicated by stimulating the growth of colonies from mouse hepatocytes suspensions on soft agar in the presence of the two compounds in vitro (119).
Latendresse and Pereira (143) also noted a number of differences in the phenotype of tumors promoted by TCA and DCA in the livers of female B6C3F, mice initiated with N-methyl-N-nitrosourea. These authors found that the majority of lesions promoted by DCA stained positively for TGF-a and glutathione S-transferase pi (GSTn). These markers were not observed in TCA-promoted lesions. Most interesting was the finding that DCA-promoted tumors expressed two cytochrome P450s not observed in the TCApromoted tumors, CYP2E1 and CYP4A1. CYP2E1 is very important to the initial metabolism of TCE, particularly at low doses (7) , indicating that metabolites would be produced in the target cell. This may be of particular importance to DCA-induced tumors.
In passing, it should be noted that the consistency of c-Jun expression noted in DCA-promoted liver tumors in MNUinitiated mice (143) was much lower than previously reported in tumors induced in male mice (117) . This could be a sex difference, but it is important to recognize that different antibodies were used in these two studies. Antibodies to c-Jun typically have been raised against different phosphorylation sites in the DNA binding or transactivation regions of the c-Jun protein. These sites are likely to be differentially affected by c-Jun activation and, as a consequence, not too much emphasis should be placed on these experimental inconsistencies until there has been some resolution of this problem.
DCA-and TCA-promoted tumors differ in other ways. Tao and co-workers (144) report that cytosine methylation was depressed in normal liver and hepatic tumors initiated by MNU during promotion with either chemical. Cessation of treatment with DCA resulted in a return of cytosine methylation in adenomas to those found in noninvolved liver and that of control animals. This response was not reversed when TCA treatment was discontinued.
The easiest explanation for these differences is that DCA and TCA selectively modify the growth rates of different clones of cells that are present in the mouse liver. It was shown that treatment of normal hepatocytes by the two compounds had no effect on these phenotypes. It is difficult to explain such consistent differences on the basis of a genotoxic mode of action. These differences are much more easily explained by suggesting that the two chemicals interact with differing cell signal pathways in liver cells that already possess a modified genotype that renders them more sensitive to one compound or the other.
Probability That TCE Is Hepatocarcinogenic in Humans
The assessment of whether TCE poses a risk of liver cancer to humans first requires consideration of the available epidemiological literature. To the extent that epidemiological data are less than conclusive, the analysis must focus on the available data in experimental animals. To extrapolate with confidence, it is necessary to understand how the tumors are produced in the sensitive species and whether humans share a similar sensitivity. It is apparent from considerations above that both TCA and DCA have properties associated with tumor promotion. However, there are distinct differences in the types of lesions that they induce. One metabolite (TCA) appears capable of inducing tumors in only a single species, whereas the other (DCA) produces tumors in both rats and mice. The early effects of DCA on the liver of the dog suggest that this species may be even more sensitive to low-dose effects of this metabolite. Therefore, some further understanding of the mechanisms by which TCA and DCA act is necessary if TCE's potential to induce liver cancer in humans is to be determined with certainty. At this stage, deciding whether humans are sensitive is not based on strict comparisons of data generated in human versus test animal systems (in vivo or in vitro). Thus, at best a series of testable hypotheses (discussed below) can be suggested. Essentially, these reduce to the development of appropriate pharmacodynamic parameters that can be applied to measuring the relative intrinsic sensitivity of human livers in in vitro. Then pharmacokinetic models can be applied to account for kinetic and metabolic similarities and differences between species and across dose ranges. This would allow the probability that humans are at risk from TCE to be more precisely defined.
Simplistically, determination of the mode by which TCE induces liver tumors in mice must first consider: a) the effects that have been correlated with tumorigenesis by TCE, b) the extent to which these effects are accounted for by particular metabolites, and c) what levels of the particular metabolite must be achieved within the liver to produce their effects. A key finding that can be exploited is the fact that hepatic tumors induced by DCA can be distinguished from those induced by TCA; this can then be extended to identifying which of these characteristics are found in tumors induced by TCE.
Effect ofTCE Associated with Liver Tumor Induction
For the purposes of this review, it may be concluded that there is no evidence that clearly associates a genotoxic effect of TCE or its hepatocarcinogenic metabolites with the induction of liver cancer. Essentially, this conclusion is based upon the weak mutagenic activity of the metabolites relative to the concentrations that are produced in the metabolism of TCE in vivo and evidence that other mechanisms are operative at these systemic concentrations.
Among the metabolites of TCE that are capable of inducing liver tumors, only CH has produced consistent genotoxic effects. These have been clastogenic rather than point mutations. The likelihood that CH contributes as a genotoxin to the carcinogenic effects of TCE appears remote. The rapid metabolism of this compound limits its concentrations to almost nonmeasurable levels, even in mice. Mice inhaling 600 ppm TCE have blood levels of 1.22 pg/ml (145) , whereas approximately 150 pg CH/ml are observed with intravenous doses of 100 mg/kg of CH (146) . While not directly comparable, these data suggest that there is a wide disparity in blood levels of CH when TCE is administered than when CH is administered directly. As a consequence, it seems more probable that the metabolites DCA and/or TCA are responsible for the carcinogenic effects of TCE.
Elcombe et al. (67) (67, 68) . Stimulatory effects have also been reported for DCA at 2 and 2.6 g/L and TCA at concentrations in drinking water of 0.32-3.2 g/L (117, 121) . Almost all investigators have observed a depression of hepatocyte replication with continued treatment with both compounds (121, 137) .
It is remarkable how well the effects of DCA and TCA on cell division conform with their respective dose-response curves for cancer induction. The nonlinear relationships with dose in DCA-induced liver tumorigenesis, whether observed when bioassayed as a complete carcinogen (73, 74) or as a promoter in an initiation-promotion study (113) , are consistent with the differential inhibition of normal cell replication at low doses and the marked stimulation of replication within tumors at high doses (117) . Conversely, the apparent linear dose-response curve with TCA-induced cancer under similar circumstances (73, 74, 113) is consistent with the fact that only the differential suppression of normal cell replication was observed (117) . While the mechanisms of action of these two chemicals appear to be distinct, these data suggest that both are acting primarily through modification ofcell birth and death processes.
The principal difference in the mechanisms of DCA (73, 114) .
While the mechanisms underlying these modifications of cell division and death are not yet known, these findings frame a mode of action for TCE-induced liver cancer that is not dependent upon chemically induced mutation. How are these findings to be translated into an assessment of potential human risks to liver cancer induced by TCE? Most critical to the low-dose extrapolation is whether small disturbances in cellular control mechanisms have pathological consequences. If DCA-and TCAinduced mechanisms can be assumed to be good models for TCE-induced carcinogenesis, it would appear that tumors are only induced by doses of the compounds that result in significant downregulation of normal control mechanisms in normal cells. Apparently it is this negative selection process that is active at low doses of both metabolites. If sufficient perturbation has to be produced in normal cells for downregulation to be observed, then it is probable that the tumorigenic response has an effective threshold.
DCA and TCA both produce hepatomegaly in the dose ranges in which they induce hepatic cancer. In part, these changes reflect the initial effects of both chemicals on increasing cell replication rates. However, some of the effects of both compounds, but most particularly DCA in mice, are the results of cytomegaly. Empirically, it might be useful to consider TCE's effects on liver weight as an early measure of processes that may be involved in liver cancer induction. The substantive differences in the character of the liver enlargement that is induced by the two metabolites indicate that care must be taken not to carry this parallel too far.
It is clear from this analysis that there is altered control of cell replication in TCEtreated mice. These effects have been demonstrated by administering either TCE directly or one of two metabolites thought responsible for its induction of liver tumors in mice. Mutation spectra in codon 61 of the H-ras protooncogene are consistent with a role of DCA in TCE-induced liver cancer. It is unlikely that these mutations play a significant role in the initiation of the tumorigenic response to either TCE or DCA because these mutations are generally less abundant than the wild-type form of the gene in most tumors and therefore would not be an early event in the process (42, 45) .
Effective Levels ofTCE Metabolites
Fisher (70) has provided a review of the pharmacokinetics of TCE and its metabolites. It is necessary, however, to touch on this issue briefly to support any conclusions that a particular metabolite can be held completely or partially responsible for liver tumor induction.
TCA is the metabolite that circulates in the blood at the highest concentration in all species, including humans (81, 83, 145, 146) . Under conditions of the bioassays for TCE, it appears that there is evidence of peroxisome proliferation in mice (67) . Blood concentrations of TCA following administration of doses of TCE used in the NCI and NTP studies are in the same range required for activation of the PPARa (147). Thus, TCA can account for these observations with TCE.
The other hepatocarcinogenic metabolite is DCA, which could arise through several pathways (54, (148) (149) (150) . Recent data indicate that at carcinogenic doses of TCE, DCA in blood can be barely detected but not quanitified, and then only after its metabolism was inhibited by prior treatment (48 (48) . In contrast, concentrations of DCA in blood of mice chronically treated with 2 g DCA/L were found to be 300 pM (39 pg/ml) during the period when they were actively drinking water (5 AM.), but fall to 10% of this level 4 hr later (9 A.M.). Concentrations observed with DCA treatment at 0.5 g/L were found to be approximately 2-4 pM (250-500 ng/mL) during the night (47), but these concentrations fell rapidly to levels below the limit of quantitation by 9 A.M. Thus, the concentrations of DCA in the blood of mice treated with 1,000 mg/kg TCE (2 gM) may be within range of a concentration that appears effective in producing liver cancer in mice treated with 0.5 g/L DCA directly. These concentrations are within an order of magnitude of those that produced clonal expansion of cells sensitive to DCA in vitro (20 ,uM) (119) . Other more complex mechanisms may be active in the intact animal, possibly an indirect mechanism that stems from differential accumulation of glycogen in normal liver cells and liver tumor cells (73) . This type of mechanism would require interactions between the initiated cells and adaptation of serum hormone levels to effects produced in normal hepatocytes. Modeling such complex responses has not been attempted in an in vitro system. The complex differences that result from differing modes of DCA and TCE administration make further comparisons difficult without additional data. However, TCE still may be metabolized to DCA in quantities that it could contribute to the carcinogenic response.
DCA is unlikely to contribute to the induction of peroxisome synthesis at levels that are produced by the metabolism of TCE. Maloney and Waxman (147) found that concentrations in the range of 0.5-1 mM are necessary to activate the PPARa. These concentrations are about three orders of magnitude higher than would be produced from the metabolism of TCE and the concentrations of DCA that result from the direct administration of DCA at doses that are dearly carcinogenic in the mouse.
A direct role for CH in the induction of liver tumors is difficult to establish because it is largely converted to TCA in vivo (146) . A possibility of it making an independent contribution to hepatocarcinogenicity of TCE is of concern because, as discussed above, this metabolite appears to be clastogenic. The (156) . The destiny of these mutated cells is known to depend on a number of factors too numerous to deal with here. However, it is clear from animal studies that while many cells become initiated, the probability that they will grow and progress to tumor is small (157) . Conversely, we know from human experience that such rare events underlie the development of cancer (158) . The question is whether mutation rate is really the ratelimiting process. Survival and replication of initiated cells may actually be more important with some environmental carcinogens.
In a similar fashion, the impact of suppressed apoptosis may be short-lived if exposure is intermittent. What is the fate of a stem cell whose death has been temporarily postponed? Are As stated earlier, there must be some differential effect of a chemical on normal cells and initiated cells for it to be an effective promoter of cancer. It is probable that such differential sensitivity will arise from a lessor ability of the initiated cell to downregulate the system responding to the chemical treatment. To some extent this appears to be characteristic of both DCA and TCA, despite the fact that they tend to stimulate growth of tumors with different characteristics. From the work of Stauber and Bull (117) , the initial stimulation of cell replication within the normal cell population appears to be followed not only by a loss of sensitivity to the mitogenic effects of the compound but also by an actual inhibition of cell replication. In neither case was the rate of replication among initiated cells so reduced. In the case of DCA, the initiated cells contained within nodules or tumors appear to retain their sensitivity to the mitogenic effects of higher doses, but the downregulation of normal cell replication appeared to be the predominant effect at lower doses. This general mode of action has been associated with other tumor promoters such as phenobarbital (118) . A critical question that arises from this observation is whether there is any increased risk for cancer from chemicals that act this way at doses below those that result in downregulation of the mitogenic response. If increased risk could be established, then there would be a clear basis for considering threshold exposure levels for tumor-promoting agents. If this can be shown, the next question is how to experimentally identify the doses at which this occurs.
For experimentalists, the critical question is whether the probability of a tumorigenic response can be quantitatively associated with a transition between a physiologically responsive pathway, one that has been downregulated to the point that it is no longer responsive to normal variations in physiological conditions. There is a concordance in the dosing schedules of DCA and TCA that produce downregulation of a mitogenic effect of the chemicals on normal cells and those that produce hepatic tumors in mice (71, 113, 117, 137) . While this dosing level with DCA produces > 80% incidence of tumors in mice over a lifetime, there is no evidence of carcinogenic response at dosing levels one order of magnitude lower (71, 76) . To In the case of DCA, understanding the effects of chronic TCE-treatment on serum insulin levels and normal hepatocyte and liver tumor cell levels of insulin receptor expression would be useful in determining the extent to which DCA plays a role in the induction of liver tumors. Clearer delineation of perturbations induced by either metabolite in cell-signaling pathways will allow the direct measures of human responses to be evaluated. These biomarkers of effect could greatly facilitate evaluation of whether humans are at significant risk of liver cancer from TCE and several other related solvents. In the case of both TCA and DCA, there is a clear path for comparing human and rodent sensitivities to these metabolites of TCE using the in vitro clonal expansion system described by Stauber et al. (117) .
Behavior ofthe Mechanisms ofIver Tumor Induction at Low Doses
One must continually keep in mind that evidence of tumorigenic response to TCE and its metabolites has been obtained only at very high doses. Virtually all of the concern that is generated about the low levels of TCE that are encountered in the general environment come from the application ofa linear extrapolation model to what appear to be strainspecific responses obtained at these very high doses. The use of the linear model for dose-response modeling is based upon assumptions about a genotoxic mode of action of TCE and its metabolites in the induction of liver cancer. Data have emerged that indicate that this assumption does not apply. Evidence is growing that DCA and TCA act primarily by modifying cell-signaling systems. Since the activity of cell-signaling systems is constantly modified as part of normal physiological function, it seems unlikely that perturbations that do not take them outside their normal operating limits are going to have irreversible and cumulative effects. This hypothesis is testable using variations in the clonal expansion system used by Stauber et al. (117) and by in vivo experiments that more precisely pursue the effects of TCE's metabolites on rates of cell division and cell death within initiated cell populations at low doses.
